Healthcare Providers' Perspectives on Psychedelic-Assisted Therapies Across Clinical Contexts: "I Can Offer Medical Assistance in Dying, but I Can't Prescribe Psychedelics".
Haley D M Schuman, Raèf Mina, Sofia Barkova, Tina Nguyen, Julie M Deleemans, Linda E. Carlson
Global Advances in Integrative Medicine and Health 2026 DOI: 10.1177/27536130261459354 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Qualitative study Peer reviewed |
|---|---|
| Sample size | 12 |
| Population | Healthcare providers across Canada |
| Topics | Ketamine MDMA Psilocybin Psychedelic-assisted therapy |
| Keywords | Cancer Integrativeoncology Psychedelics |
| Key findings | Healthcare providers' attitudes toward psychedelic-assisted therapy ranged from caution to advocacy, with substantial ethical, regulatory, and systemic constraints to clinical integration, including a notable ethical tension between medical assistance in dying accessibility and psychedelic-assisted therapy restrictions in end-of-life contexts. |
Abstract
Healthcare providers' (HCPs) perspectives on psychedelic-assisted therapy (PAT) are critical to clinical integration but remain underexplored in Canadian palliative and oncology contexts. This study examines HCP attitudes toward ketamine, psilocybin, and MDMA, and the systemic and ethical factors influencing implementation. An exploratory qualitative study using semi-structured interviews was conducted with 12 HCPs across Canada. Interviews explored attitudes, perceived barriers, and implementation considerations. Data were analyzed using thematic analysis and interpreted through the Theory of Planned Behaviour (TPB) to examine how attitudes, subjective norms, and perceived behavioural control shape clinical integration. Attitudes toward PAT ranged from caution to advocacy, with neutral-to-cautious positions predominating. Ketamine was pragmatically accepted for rapid efficacy but raised concerns regarding commercialization and misuse. Psilocybin elicited mixed views, particularly in relation to end-of-life existential distress. MDMA was considered promising for trauma-related indications but was constrained by neurotoxicity concerns and regulatory barriers. Subjective norms were shaped by stigma, media narratives, and institutional culture, while perceived behavioural control was limited by restrictive policies, infrastructure gaps, and funding inequities. An ethical tension emerged between access to medical assistance in dying (MAiD) and restrictions on PAT in end-of-life care, highlighting perceived policy inconsistencies. Participants expressed a range of attitudes toward PAT, from caution to advocacy, alongside substantial ethical, regulatory, and systemic constraints to clinical integration. A notable ethical tension emerged between MAiD accessibility and PAT restrictions in end-of-life contexts, reflecting broader questions about Canadian health policy. Participants emphasized the need for substance-specific guidelines, interdisciplinary education, and evidence-informed regulatory reform to guide future clinical consideration of PAT.
Comparable studies
Other qualitative studies on MDMA, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Phenomenology and Sequelae of 3,4-Methylenedioxymethamphetamine Use Psychiatrists who had taken MDMA | 1992 | Qualitative study | n = 20 |
| MDMA and Sexual Behavior: Ecstasy Users' Perceptions About Sexuality and Sexual Risk Current and former users of MDMA | 2005 | Qualitative study | n = 98 |
| Perceived Benefits of MDMA-Assisted Psychotherapy beyond Symptom Reduction: Qualitative Follow-Up Study of a Clinical Trial for Individuals with Treatment-Resistant PTSD Veterans, firefighters, and police officers with chronic, treatment-resistant PTSD | 2019 | Qualitative study using interpretative phenomenological analysis | n = 19 |
| Negative Experiences on Ecstasy: The Role of Drug, Set, and Setting Current or former users of Ecstasy | 2002 | Qualitative study | n = 98 |
| A Qualitative Exploration of Relational Ethical Challenges and Practices in Psychedelic Healing Practitioners who have administered MDMA and psilocybin to clients in underground... | 2021 | Qualitative study | n = 23 |
Citations in the library
Cites 69
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms Pharmacological Reviews June 26, 2018
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
- REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics Pharmacological Reviews June 20, 2019
and 64 more in the library